Mayne Pharma Group ( (AU:MYX) ) has issued an update.
Mayne Pharma Group Limited is involved in a legal proceeding initiated by TherapeuticsMD, Inc. in the United States, alleging various breaches related to a Transaction Agreement from December 2022. Mayne Pharma plans to defend the claims vigorously and has counterclaims against TherapeuticsMD, asserting damages exceeding those claimed by the plaintiff. The company denies any wrongdoing and maintains that the proceeding will not affect existing agreements or rights concerning licensed products.
More about Mayne Pharma Group
Mayne Pharma is an ASX-listed specialty pharmaceutical company that focuses on commercializing novel pharmaceuticals, particularly in dermatology and women’s health. The company also provides contract development and manufacturing services globally and has a 40-year history of innovation in oral drug delivery systems.
YTD Price Performance: 46.01%
Average Trading Volume: 2,306
Technical Sentiment Signal: Sell
Current Market Cap: $344M
See more insights into MYX stock on TipRanks’ Stock Analysis page.